RARE - Ultragenyx Pharmaceutical Inc.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.
Martin Shkreli, known as Pharma Bro, said Ultragenyx Pharmaceutical (NASDAQ:RARE) is undervalued and a potential takeover target for rare-disease peers like BioMarin Pharmaceuticals (NASDAQ:BMRN) after a trial setback.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock is tumbling on Thursday after reporting late-stage clinical trial failures for its Angelman syndrome therapy, apazunersen, prompting the biopharmaceutical firm to review the program's future and plan significant corporate expense reductions.
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.
Ultragenyx Pharmaceuticals looks to cut costs following the trial failure, while attention remains squared on its burgeoning commercial business.
Shares of Ultragenyx Pharmaceutical plunged more than 40% in premarket on Thursday after its neurodevelopmental disorder treatment failed a closely watched late-stage trial, dealing a major blow to one of its biggest growth bets.
Ultragenyx Pharmaceutical said on Wednesday its experimental drug for a rare genetic neurodevelopmental disorder did not meet the main goal in a late-stage trial, sending its shares down 40% in aftermarket trading.
Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI)
At Week 96, participants across treatment and crossover groups experienced mean reduction in daily cornstarch intake of 61% while maintaining glycemic control, with most participants achieving reduction of at least 50%
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,984 restricted stock units of the company's common stock to 23 newly hired non-executive officers of the company.
Deutsche Bank AG purchased a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 164,813 shares of the biopharmaceutical company's stock, valued at approximately $5,503,000. Deutsche Bank AG owned about 0.17% of
Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares are up during Thursday's premarket session on the recent U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr, or DTX401).
Ultragenyx Pharmaceutical NASDAQ: RARE said the U.S. Food and Drug Administration has approved GENGLYCOS, also known as DTX401, for glycogen storage disease type 1A, or GSD1A. The approval marks the company's first gene therapy approval and its fifth approved medicine.
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript
The U.S. Food and Drug Administration approved Ultragenyx Pharmaceutical's gene therapy to treat a rare metabolic disorder, the company said on Wednesday.
GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to reduce the burden of care associated with GSDIa Ultragenyx received a Priority Review Voucher upon approval Ultragenyx to host conference call on 8/19/26 at 6:00 p.m. Eastern Time NOVATO, Calif.